Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

書目詳細資料
發表在:	Pharmacological Research
Main Authors:	Paula Zapata-Cobo, Sara Salvador-Matín, Marta Velasco, Laura M. Palomino, Susana Clemente, Oscar Segarra, Ana Moreno-Álvarez, Ana Fernández-Lorenzo, Begoña Pérez-Moneo, Montse Montraveta, Cesar Sánchez, Mar Tolín, Inés Loverdos, María José Fobelo, Victor Manuel Navas-López, Lorena Magallares, Ruth García-Romero, José Germán Sánchez-Hernández, Alejandro Rodríguez, Ferrán Bossacoma, María Jesús Balboa, Enrique Salcedo, María Sanjurjo-Sáez, Luis A. López-Fernández
格式:	Article
語言:	英语
出版:	Elsevier 2023-10-01
主題:	Inflammatory bowel disease Pharmacogenetics Infliximab Adalimumab Polymorphism Pediatric
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S1043661823002943

相似書籍

Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
由: Paula Zapata-Cobo, et al.
出版: (2023-08-01)

Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
由: Sara Salvador-Martín, et al.
出版: (2021-01-01)

Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis
由: Tatyana Valentinovna Mezenova, et al.
出版: (2012-04-01)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
由: Yoon Suk Jung, et al.
出版: (2021-01-01)

Pregnancy Recommendations Solely Based on Preclinical Evidence Should Be Integrated with Real-World Evidence: A Disproportionality Analysis of Certolizumab and Other TNF-Alpha Inhibitors Used in Pregnant Patients with Psoriasis
由: Mario Gaio, et al.
出版: (2024-07-01)

Therapeutic Drug Monitoring of Anti-TNFα Inhibitors: A Matter of Cut-Off Ranges
由: Stefania Cheli, et al.
出版: (2023-06-01)

Comparison of long-term outcomes of infliximab and adalimumab therapy in biologic-naive patients with ulcerative colitis
由: Muhammed B. Durak, et al.
出版: (2025-01-01)

Factors Contributing to the Preference of Korean Patients with Crohn’s Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
出版: (2016-05-01)

Safety profile and side effects of infliximab and adalimumab in inflammatory bowel disease at a referral center in northeastern Brazil
由: Joelma Aurélio de Sousa Santos, et al.
出版: (2024-02-01)

Validation of the i-Tracker Drug and Total Anti-Drug Antibody CLIA Assays on IDS-iSYS for Therapeutic Drug Monitoring in Adalimumab- and Infliximab-Treated Patients
由: Akpedje Serena Dossou, et al.
出版: (2025-09-01)

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
由: Sara Salvador-Martín, et al.
出版: (2021-10-01)

Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA
由: Francisco José Toja-Camba, et al.
出版: (2023-11-01)

New Treatment Alternatives in the Management of Non-‹nfectious ‹ntraocular ‹nflammations: Biologic Agents
由: Sinan Emre, et al.
出版: (2011-08-01)

BIOLOGICAL TREATMENT IN PATIENTS WITH REFRACTORY BEHÇET’S UVEITIS: A RETROSPECTIVE SINGLE-CENTRE STUDY
由: Dilbade Yıldız Ekinci, et al.
出版: (2025-09-01)

Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs
由: Anna Pau, et al.
出版: (2025-01-01)

Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
由: Yoo Min Lee, et al.
出版: (2022-01-01)

Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives
由: Gerardo Cazzato, et al.
出版: (2021-08-01)

Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis
由: Bruna O. Ascef, et al.
出版: (2021-07-01)

Refractory multisystemic sarcoidosis, a diagnosis and treatment challenge: a case report
由: Jorge Luis Rodas Flores, et al.
出版: (2023-06-01)

Diagnóstico de la tuberculosis latente en la era de la terapia biológica
由: María Carolina Ruiz, et al.
出版: (2019-02-01)

Targeting psoriasis with new therapies
由: A.Prohić;H. Helppikangas;J. Muhović
出版: (2007-08-01)

Outcome of cataract surgery in juvenile idiopathic arthritis-associated uveitis under two different biological regimens
由: Mariam R Fadel, et al.
出版: (2024-10-01)

Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
由: Ju Young Kim, et al.
出版: (2021-07-01)

Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
由: Mohammad Shehab, et al.
出版: (2021-12-01)

Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis
由: Weishai Liu, et al.
出版: (2023-05-01)

Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
由: Rintaro Moroi, et al.
出版: (2019-01-01)

Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
由: Jang Wook Lee, et al.
出版: (2016-04-01)

Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα
由: Júlio César Bertacini de Moraes, et al.

Comparison Between Adalimumab and Infliximab in Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis
由: Tarek Aboursheid, et al.
出版: (2025-01-01)

HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE
由: A. S. Kolbin, et al.
出版: (2016-12-01)

Correlation of anti-TNF-a biological therapy with periodontal conditions and osteonecrosis in autoimmune patients: A systematic review
由: Rana Majdi Abunemer, et al.
出版: (2023-11-01)

TNF-alpha blockers in inflammatory bowel diseases: Practical consensus recommendations and a user's guide
由: C Felley
出版: (2009-05-01)

Clinical profile and management with immunosuppressants and biologics in Behcet's uveitis: A cohort of 25 patients from a tertiary eye care center in South India
由: Jeyasooriya Ramdoss, et al.
出版: (2023-01-01)

Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa
由: Rene Chen, et al.
出版: (2024-02-01)

Treatment of Ulcerative Colitis: Impact on Platelet Aggregation
由: Sasa Peric, et al.
出版: (2023-09-01)

Switching Among Biosimilars: A Review of Clinical Evidence
由: Eleonora Allocati, et al.
出版: (2022-08-01)

Safety profile of anti-tumor necrosis factor therapy in inflammatory bowel disease – a single center experience
由: Piotr Eder, et al.
出版: (2015-09-01)

Impact of Biologic Treatment of Crohn’s Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland
由: Przemysław Holko, et al.
出版: (2018-06-01)

Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis
由: Han Wang, et al.
出版: (2022-11-01)

Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
由: Raquel Campanilho-Marques, et al.
出版: (2020-04-01)